N J R Lyons1, S Pathak2, I R Daniels2, A Spiers3, N J Smart2. 1. Exeter Surgical Health Service Research Unit (HeSRU), Royal Devon and Exeter Hospital, Barrack Road, Exeter, Devon, EX2 5DW, UK. Electronic address: nicholaslyons@hotmail.co.uk. 2. Exeter Surgical Health Service Research Unit (HeSRU), Royal Devon and Exeter Hospital, Barrack Road, Exeter, Devon, EX2 5DW, UK. 3. Department of Radiology, Royal Devon and Exeter Hospital, Barrack Road, Exeter, Devon, EX2 5DW, UK.
Abstract
BACKGROUND: Radiofrequency ablation (RFA) is a well-established treatment modality for colorectal hepatic metastases, the success of which has prompted its use to treat other lesions such as colorectal pulmonary metastases (CRPM). Our aim was to perform a systematic review of the evidence and to assess the safety and effectiveness of ablative techniques in the management of CRPM. METHOD: A literature search was performed using PubMed, Embase, Cochrane Library, CINAHL and Google scholar databases to identify studies, which analysed ablative techniques and their effectiveness in the management of CRPM. The primary outcome measures were overall survival, local recurrence rates and disease free survival. Secondary outcome measures were complication (major/minor), chest drain insertion rates and follow up duration. RESULTS: Eight studies were included in the review with a total of 903 patients and all of which used RFA for ablation. Mortality from ablation was <1% with overall survival ranging from 31 to 67 months. 1, 3 and 5 year survival ranges of 84-95%, 35-72% and 20-54% respectively. Local progression following ablation ranged from 9 to 21%. Major complication rates were noted in 0.5%-8% of patients with minor complications ranging between 7% and 33%. 23% of patients required chest drain insertion post procedure. CONCLUSION: s: RFA is a safe and effective technique for the management of CRPM. However, in the absence of large randomised controlled trials it is unclear where RFA should sit in the treatment algorithm for patients with CRPM.
BACKGROUND: Radiofrequency ablation (RFA) is a well-established treatment modality for colorectal hepatic metastases, the success of which has prompted its use to treat other lesions such as colorectal pulmonary metastases (CRPM). Our aim was to perform a systematic review of the evidence and to assess the safety and effectiveness of ablative techniques in the management of CRPM. METHOD: A literature search was performed using PubMed, Embase, Cochrane Library, CINAHL and Google scholar databases to identify studies, which analysed ablative techniques and their effectiveness in the management of CRPM. The primary outcome measures were overall survival, local recurrence rates and disease free survival. Secondary outcome measures were complication (major/minor), chest drain insertion rates and follow up duration. RESULTS: Eight studies were included in the review with a total of 903 patients and all of which used RFA for ablation. Mortality from ablation was <1% with overall survival ranging from 31 to 67 months. 1, 3 and 5 year survival ranges of 84-95%, 35-72% and 20-54% respectively. Local progression following ablation ranged from 9 to 21%. Major complication rates were noted in 0.5%-8% of patients with minor complications ranging between 7% and 33%. 23% of patients required chest drain insertion post procedure. CONCLUSION: s: RFA is a safe and effective technique for the management of CRPM. However, in the absence of large randomised controlled trials it is unclear where RFA should sit in the treatment algorithm for patients with CRPM.
Authors: I Kurilova; A Gonzalez-Aguirre; R G Beets-Tan; J Erinjeri; E N Petre; M Gonen; M Bains; N E Kemeny; S B Solomon; C T Sofocleous Journal: Cardiovasc Intervent Radiol Date: 2018-05-29 Impact factor: 2.740
Authors: Markus W Löffler; Bianca Nussbaum; Günter Jäger; Philipp S Jurmeister; Jan Budczies; Philippe L Pereira; Stephan Clasen; Daniel J Kowalewski; Lena Mühlenbruch; Ingmar Königsrainer; Stefan Beckert; Ruth Ladurner; Silvia Wagner; Florian Bullinger; Thorben H Gross; Christopher Schroeder; Bence Sipos; Alfred Königsrainer; Stefan Stevanović; Carsten Denkert; Hans-Georg Rammensee; Cécile Gouttefangeas; Sebastian P Haen Journal: Front Immunol Date: 2019-11-19 Impact factor: 7.561
Authors: Jim Zhong; Ebrahim Palkhi; Helen Ng; Kevin Wang; Richard Milton; Nilanjan Chaudhuri; James Lenton; Jonathan Smith; Bobby Bhartia; Tze Min Wah Journal: Cardiovasc Intervent Radiol Date: 2020-08-18 Impact factor: 2.740
Authors: Raghav Chandra; John D Karalis; Charles Liu; Gilbert Z Murimwa; Josiah Voth Park; Christopher A Heid; Scott I Reznik; Emina Huang; John D Minna; Rolf A Brekken Journal: Cancers (Basel) Date: 2021-12-09 Impact factor: 6.639